Moreover, recent findings suggest that decitabine may boost platelet production through immune regulation, particularly by enhancing Treg cell activity and reducing the promoter methylation status of TRAIL, as observed in studies addressing refractory immune thrombocytopenia (23, 24). This evidence concerns the gene TNFSF10 and autoimmune thrombocytopenic purpura.